Novo Nordisk Q1 2026 earnings beat on Wegovy pill demand
Novo Nordisk raised its full-year guidance on Wednesday after first-quarter sales of its Wegovy weight loss pill came…
Novo Nordisk (NVO) lifts 2026 outlook as obesity drug demand remains strong
Wegovy ©Novo Nordisk Novo Nordisk (NYSE:NVO) raised its full-year guidance on Wednesday, citing continued strong demand for its…
Is Novo Nordisk’s Turnaround Story at Risk After Weak 2026 Outlook?
Novo Nordisk NVO announced better-than-expected fourth-quarter and full-year results last week. The company is a dominant player in the cardiometabolic…